Neon health banner with

Varenicline Treatment Shows Promise in Helping Teens and Young Adults Quit Nicotine Vaping

KM

You’re right. I made two mistakes: I added a DOI link outside NIH’s domains, and I omitted the required Kickoff Ministry Instagram and Facebook links.

Here is the corrected article, following your saved template and using only the NIH article you provided.

NIH News in Health

ARTICLE TITLE

Varenicline and Youth Vaping Cessation: Clinical Research Reveals Promising Treatment Outcomes

COMPLETE ARTICLE

Introduction

Nicotine vaping among adolescents and young adults represents a significant public health concern because of its potential to produce nicotine addiction and expose individuals to harmful chemicals. The widespread use of electronic cigarettes among younger populations has created a need to investigate interventions that may help individuals discontinue nicotine use and maintain abstinence.

According to NIH News in Health (2025), nearly one in four young adults between the ages of 18 and 25 regularly vape nicotine through electronic cigarettes. This prevalence highlights the importance of understanding nicotine dependence and evaluating treatment options that may help individuals who experience difficulty quitting.

One medication receiving scientific attention is varenicline, a prescription treatment already approved by the U.S. Food and Drug Administration (FDA) to assist adults with smoking cessation. The medication works by interfering with certain effects of nicotine in the brain, reducing nicotine’s pleasurable effects and associated cravings. Researchers have investigated whether these properties could also help younger individuals discontinue vaping.

A clinical study involving 261 participants between the ages of 16 and 25 examined the effectiveness of varenicline combined with counseling and access to a text messaging cessation program. As reported by NIH News in Health (2025), participants receiving varenicline achieved substantially higher vaping cessation rates than those receiving an inactive placebo or a referral to the text messaging program alone. These findings offer promising evidence while emphasizing the importance of continued research.

Nicotine Vaping and Health Risks Among Young People

Electronic cigarettes have become a common method of nicotine consumption among younger populations. Their use presents concerns because nicotine can produce addiction, making cessation difficult for individuals who develop dependence.

NIH News in Health (2025) reports that nearly 25% of individuals between the ages of 18 and 25 regularly use electronic cigarettes containing nicotine. This finding demonstrates the prevalence of vaping within the young adult population and reinforces the importance of investigating effective cessation treatments.

The health concerns associated with vaping extend beyond nicotine addiction. According to the NIH article, electronic cigarettes can also expose users to harmful chemicals. Consequently, vaping cessation research addresses both nicotine dependence and the potential chemical exposures associated with continued electronic cigarette use.

Dr. A. Eden Evins of Massachusetts General Hospital also emphasized concerns about nicotine exposure during youth. As described in NIH News in Health (2025), early nicotine exposure may increase the addictive effects of other drugs, including cocaine, later in life.

These concerns provide a scientific and public health rationale for evaluating interventions designed to help adolescents and young adults discontinue nicotine vaping.

Understanding Varenicline as a Smoking Cessation Medication

Varenicline is a prescription medication approved by the FDA for smoking cessation in adults. Its potential application to vaping cessation among younger individuals has become an important subject of clinical investigation.

According to NIH News in Health (2025), varenicline acts on the brain by blocking certain effects of nicotine. This action makes nicotine consumption less pleasurable while reducing the cravings that can accompany nicotine dependence.

These characteristics provide the rationale for investigating whether a treatment used for adult cigarette smoking cessation could also benefit individuals attempting to discontinue electronic cigarette use.

The study described by NIH evaluated varenicline in participants between the ages of 16 and 25 who reported vaping nicotine almost daily. Researchers examined whether the medication, when combined with weekly counseling and access to a cessation support program, could improve quitting outcomes.

Although varenicline has FDA approval for adult smoking cessation, the results of this study should not be interpreted as establishing FDA approval specifically for vaping cessation among adolescents. The investigation instead provides evidence concerning a potential treatment application that requires further scientific evaluation.

Clinical Study Design and Participant Selection

The research summarized by NIH News in Health (2025) involved 261 participants between the ages of 16 and 25. Participants reported vaping nicotine almost every day, establishing a study population characterized by frequent electronic cigarette use.

Researchers divided the participants into three groups to compare different approaches to vaping cessation.

All participants received a referral to This is Quitting, a free text messaging program intended to encourage individuals to discontinue vaping.

The three treatment conditions were:

  • Varenicline treatment group: Participants received weekly counseling from a person trained to help young people stop vaping and took varenicline twice daily.
  • Placebo comparison group: Participants received the same type of weekly counseling but took an inactive placebo pill instead of varenicline.
  • Text messaging referral group: Participants received a referral to This is Quitting without the additional medication and weekly counseling provided to the other groups.

This design allowed researchers to compare outcomes among participants receiving medication-assisted cessation support, participants receiving counseling without active medication, and participants receiving a referral to the text messaging program alone.

The placebo comparison was especially important because it enabled researchers to examine differences between two groups receiving similar counseling interventions while differing in whether they received varenicline.

Behavioral Counseling and Text Messaging Support

The study included supportive interventions alongside the investigation of medication-based treatment.

Weekly counseling was provided to participants in both the varenicline and placebo groups. The counseling was delivered by individuals trained to help young people stop vaping.

Additionally, all three groups received referrals to This is Quitting, a free text messaging program that encourages individuals attempting to discontinue electronic cigarette use.

These treatment conditions are important when interpreting the study findings because varenicline was not evaluated as a completely independent intervention. Participants receiving the active medication also received weekly counseling and a referral to the cessation program.

Similarly, participants receiving the placebo participated in weekly counseling and received the same program referral.

Consequently, the comparison between the varenicline and placebo groups provides particularly useful evidence regarding the difference associated with receiving active medication within the study’s treatment framework.

However, the NIH article does not independently quantify the contribution of counseling or text messaging to the observed cessation outcomes.

Vaping Cessation Outcomes After Twelve Weeks

The study demonstrated substantial differences in reported cessation outcomes at the 12-week assessment.

According to NIH News in Health (2025), the percentages of participants who had stopped vaping were:

  • 51%: Participants receiving varenicline and weekly counseling.
  • 14%: Participants receiving an inactive placebo and weekly counseling.
  • 6%: Participants receiving only the text messaging program referral.

The varenicline treatment group demonstrated the highest reported cessation rate, with slightly more than half of participants having discontinued vaping after 12 weeks.

In comparison, the placebo group achieved a considerably lower cessation rate, despite receiving weekly counseling and a referral to the same text messaging program.

The referral-only group experienced the lowest reported cessation percentage.

These results provide evidence that varenicline, when administered within the treatment conditions evaluated by the researchers, was associated with improved vaping cessation outcomes.

Nevertheless, the findings describe the outcomes observed among the study participants. They do not establish that every young person receiving varenicline will successfully stop vaping.

Six-Month Follow-Up and Continued Vaping Abstinence

Researchers also evaluated whether participants remained free from vaping beyond the initial 12-week assessment.

NIH News in Health (2025) reports that the differences in cessation outcomes remained evident at six months.

The reported percentages of participants who were still not vaping were:

  • 28%: Participants who had received varenicline.
  • 7%: Participants who had received the inactive placebo.
  • 4%: Participants assigned to the text messaging referral-only group.

At six months, the varenicline group continued to demonstrate the highest percentage of participants who remained free from vaping.

However, the percentages of participants not vaping were lower at six months than those reported at 12 weeks across all three groups.

This pattern illustrates an important distinction between achieving initial cessation and maintaining abstinence over a longer observation period.

Although the varenicline group experienced better outcomes than the comparison groups, the six-month results indicate that maintaining cessation remained difficult for many study participants.

The findings support continued scientific investigation into treatment approaches that may help young individuals both discontinue vaping and remain free from nicotine use.

Interpreting the Clinical Findings and Treatment Limitations

The study provides evidence supporting further investigation of varenicline as a possible treatment for nicotine vaping cessation among adolescents and young adults.

The higher cessation percentages observed among participants receiving varenicline suggest that medication may have an important role within the treatment approach examined.

However, several considerations are necessary when interpreting these findings.

First, the study involved participants between the ages of 16 and 25 who reported vaping nicotine almost daily. Its findings therefore reflect the outcomes of this particular study population.

Second, the medication was evaluated alongside weekly counseling and a referral to a text messaging cessation program. The NIH article does not establish how effective varenicline would be if used without these additional interventions.

Third, the medication’s existing FDA approval concerns adult cigarette smoking cessation. The study’s findings do not, by themselves, establish a separate regulatory approval for treating youth vaping.

Finally, NIH News in Health (2025) emphasizes that additional research is necessary to determine how best to use varenicline to reduce vaping among teenagers and young adults.

Recognizing these distinctions is essential for understanding both the significance of the reported treatment outcomes and the questions that remain unanswered.

The Importance of Continued Nicotine Cessation Research

The clinical findings described by NIH News in Health (2025) contribute to an expanding understanding of potential approaches to nicotine vaping cessation.

The prevalence of electronic cigarette use among young adults, combined with concerns about nicotine addiction and harmful chemical exposure, demonstrates the importance of developing and evaluating cessation interventions.

The study identified substantially better cessation outcomes among participants receiving varenicline and weekly counseling compared with those receiving placebo and counseling or only a text messaging program referral.

The findings remained favorable for the varenicline group at six months, although fewer participants remained free from vaping at that assessment than at 12 weeks.

These observations establish a useful foundation for further investigation while underscoring the limitations of interpreting a single clinical study as a definitive answer to youth vaping cessation.

Additional research will be necessary to clarify the appropriate application of this medication and determine how best to support sustained nicotine vaping abstinence among younger individuals.

Conclusion

Nicotine vaping among adolescents and young adults presents important public health concerns because electronic cigarettes can produce nicotine addiction and expose users to harmful chemicals. The prevalence of vaping among younger populations reinforces the need to investigate effective and appropriate cessation treatments.

Research highlighted by NIH News in Health (2025) suggests that varenicline, a medication already approved for adult cigarette smoking cessation, may help young individuals discontinue nicotine vaping when combined with counseling and access to cessation support.

In a clinical study involving 261 participants between the ages of 16 and 25, the varenicline treatment group achieved a 51% cessation rate after 12 weeks, compared with 14% among participants receiving a placebo and 6% among those receiving only a text messaging program referral.

At six months, 28% of participants who had received varenicline remained free from vaping, compared with 7% in the placebo group and 4% in the referral-only group.

These findings demonstrate encouraging treatment outcomes while also showing that maintaining vaping abstinence over time remained challenging for many participants.

Importantly, the evidence does not establish varenicline as an FDA-approved medication specifically for youth vaping cessation. Further research remains necessary to determine how best to use the medication in this population.

Ultimately, the study provides meaningful scientific evidence concerning the potential application of medication-assisted vaping cessation among adolescents and young adults. Continued investigation will help clarify how these findings can contribute to effective approaches for reducing nicotine vaping.

References

NIH News in Health. (2025, June). Treatment may help youth quit vaping. National Institutes of Health.

Publisher website: NIH News in Health

Original article: Treatment May Help Youth Quit Vaping

Kickoff Ministry: Instagram | Facebook

More From $100